WILMINGTON, Del. - AstraZeneca’s Fasenra (benralizumab) has gained U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated vasculitis. This disease can cause damage to multiple organs and may be fatal if left untreated.
The FDA’s decision was influenced by the MANDARA Phase III trial results, which demonstrated that nearly 60% of patients treated with Fasenra achieved remission, a rate comparable to those treated with the previously approved EGPA therapy, mepolizumab. Additionally, the trial showed that 41% of patients on Fasenra were able to completely cease using oral corticosteroids, a significant improvement over the 26% in the mepolizumab group.
EGPA, also known as Churg-Strauss Syndrome, affects an estimated 15,000 patients in the U.S. The disease can lead to symptoms such as extreme fatigue, weight loss, muscle and joint pain, rashes, nerve pain, sinus and nasal issues, and shortness of breath. Current treatments often involve chronic high-dose oral corticosteroids, which can have serious side effects and may lead to recurrent relapses when doses are tapered.
Dr. Michael Wechsler, Coordinating Investigator of the MANDARA trial, highlighted the significance of this approval for patients who suffer from debilitating symptoms and rely on long-term steroid therapy. Joyce Kullman, Executive Director of the Vasculitis Foundation, also welcomed the approval, noting the disease's devastating impact on patients' quality of life.
Fasenra, already established for severe eosinophilic asthma treatment, is now the second biologic approved for EGPA. The safety and tolerability profile of Fasenra in the MANDARA trial was consistent with its known profile.
This news is based on a press release statement and indicates AstraZeneca (NASDAQ:AZN)'s commitment to addressing eosinophilic diseases beyond severe asthma. With the Orphan Drug Designation granted by the FDA in 2018, Fasenra's approval for EGPA marks another step in expanding treatment options for rare diseases.
In other recent news, AstraZeneca has reported significant developments in its HIMALAYA Phase III trial, demonstrating that its immunotherapy regimen extended the survival of patients with unresectable hepatocellular carcinoma. The trial showed a 24% reduction in the risk of death compared to sorafenib, a standard treatment. Michel Demaré, the Non-Executive Chair of the Board, purchased 2,000 shares of the company, reflecting a personal investment in the company's future. In the medical field, AstraZeneca's ENHERTU showed significant progression-free survival rates in patients with HER2-positive metastatic breast cancer who have brain metastases. Deutsche Bank, however, downgraded AstraZeneca stock from Hold to Sell due to concerns over the company's TROP2 asset datopotamab. On the other hand, BMO Capital, Erste Group, TD Cowen, and BofA Securities maintained positive outlooks on AstraZeneca shares, emphasizing the company's strong financial structure and above-average growth projection. These are the recent developments in AstraZeneca's ongoing advancements in the pharmaceutical industry.
InvestingPro Insights
AstraZeneca's recent FDA approval for Fasenra marks a significant milestone in its commitment to expanding treatment options for rare diseases. The company's strategic advancements in the pharmaceutical industry are reflected in its financial health and market performance. According to InvestingPro data, AstraZeneca boasts a robust market capitalization of $242.76B, underscoring its prominence as a key player in the sector. The company's revenue growth is also notable, with a 10.45% increase over the last twelve months as of Q2 2024, demonstrating its ability to scale operations and maintain profitability.
InvestingPro Tips highlight that AstraZeneca is expected to see net income growth this year, which aligns with the company's successful expansion into new therapeutic areas like EGPA treatment. Additionally, two analysts have revised their earnings upwards for the upcoming period, reflecting optimism in the company's financial prospects following recent developments. Moreover, AstraZeneca has maintained dividend payments for 32 consecutive years, indicating a strong commitment to shareholder returns even as it invests in research and development for innovative treatments.
Investors may note that AstraZeneca is trading at a high earnings multiple, with a P/E ratio of 37.61, suggesting a premium valuation that could be attributed to its strategic positioning and growth prospects in the pharmaceutical industry. For those interested in further analysis, InvestingPro offers additional tips on AstraZeneca, providing a deeper dive into the company's financials and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.